BriaCell Therapeutics Future Growth
Future criteria checks 0/6
BriaCell Therapeutics's earnings are forecast to decline at 15% per annum while its annual revenue is expected to grow at 65% per year. EPS is expected to grow by 37% per annum.
Key information
-15.0%
Earnings growth rate
37.0%
EPS growth rate
Biotechs earnings growth | 28.5% |
Revenue growth rate | 65.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 Sep 2024 |
Recent future growth updates
Recent updates
BriaCell stock rises on license deal for anti-cancer agent
Aug 04BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy
Jul 05BriaCell, Harvard enter research agreement to identify targets for cancer treatments
Jun 29BriaCell Therapeutics receives proceed of $12.88M from warrant exercises
Jun 10BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients
Jun 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
7/31/2027 | 10 | -50 | -78 | N/A | 1 |
7/31/2026 | N/A | -40 | -58 | N/A | 1 |
7/31/2025 | N/A | -31 | -45 | N/A | 2 |
7/31/2024 | N/A | -19 | -9 | N/A | 2 |
4/30/2024 | N/A | -6 | -31 | -31 | N/A |
1/31/2024 | N/A | -13 | -31 | -31 | N/A |
10/31/2023 | N/A | -13 | -28 | -28 | N/A |
7/31/2023 | N/A | -20 | -24 | -24 | N/A |
4/30/2023 | N/A | -18 | -16 | -16 | N/A |
1/31/2023 | N/A | -23 | -16 | -16 | N/A |
10/31/2022 | N/A | 0 | -14 | -14 | N/A |
7/31/2022 | N/A | -27 | -12 | -12 | N/A |
4/30/2022 | N/A | -42 | -11 | -11 | N/A |
1/31/2022 | N/A | -30 | -12 | -12 | N/A |
10/31/2021 | N/A | -41 | -9 | -9 | N/A |
7/31/2021 | N/A | -14 | -8 | -8 | N/A |
4/30/2021 | N/A | 2 | -6 | -6 | N/A |
1/31/2021 | N/A | -2 | -1 | -1 | N/A |
10/31/2020 | N/A | -3 | -1 | -1 | N/A |
7/31/2020 | N/A | -4 | -1 | -1 | N/A |
4/30/2020 | N/A | -4 | -1 | -1 | N/A |
1/31/2020 | N/A | -5 | -3 | -3 | N/A |
10/31/2019 | N/A | -5 | -4 | -4 | N/A |
8/1/2019 | N/A | -5 | -4 | -4 | N/A |
4/30/2019 | N/A | -5 | -4 | -4 | N/A |
1/31/2019 | N/A | -5 | -4 | -4 | N/A |
10/31/2018 | N/A | -4 | -4 | -4 | N/A |
7/31/2018 | N/A | -4 | -4 | -4 | N/A |
4/30/2018 | N/A | -3 | -3 | -3 | N/A |
1/31/2018 | N/A | -3 | N/A | -3 | N/A |
10/31/2017 | N/A | -3 | N/A | -2 | N/A |
7/31/2017 | N/A | -3 | N/A | -2 | N/A |
4/30/2017 | N/A | -2 | N/A | -2 | N/A |
1/31/2017 | N/A | -1 | N/A | -1 | N/A |
10/31/2016 | N/A | -2 | N/A | -1 | N/A |
7/31/2016 | N/A | -2 | N/A | -1 | N/A |
4/30/2016 | N/A | -2 | N/A | -1 | N/A |
1/31/2016 | N/A | -2 | N/A | -1 | N/A |
10/31/2015 | N/A | -3 | N/A | -1 | N/A |
7/31/2015 | N/A | -3 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCTX is forecast to have no revenue next year.
High Growth Revenue: BCTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCTX's Return on Equity is forecast to be high in 3 years time